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Sources of data on HCV in Bangladesh in key populations at risk
of HIV are available through various sources. The last national HIV
surveillance conducted in Bangladesh in 2011 showed that in six
cities >50% of PWID had antibodies to HCV; in the capital city of
Dhaka, HCV prevalence among PWID was 39.6%. Information from
965 clients attending theHIV testing and counselling unit of icddr,b
in 2011where HCV antibodieswere also tested also conﬁrmed that
the highest rate was in PWID (37.1%) followed by clients of FSW
(1.6%) and less than 1% in others. Geographically, populations in
Dhaka, especially old Dhaka, appear to be especially vulnerable to
blood-borne infections such as HCV and HIV. In a study conducted
in 2015 among 84 HIV positive PWID in old Dhaka, 61% were also
positive for anti-HCV antibody. However, harm reduction services
have been active in Bangladesh and the needle syringe program is
among the best in South Asia. The prevalence of HCV has signiﬁ-
cantly declined in PWID in Dhaka since 1998 which appears to be
a direct result of these services.
Hepatitis C virus shows considerable sequence variability in its
genome and has at least 6 genotypes which respond differently
to available therapeutics. In Bangladesh, RNA from 81 samples
obtained through different studies at different times were ampli-
ﬁed for genotyping; 3a was the most prevalent (59.3%) followed by
3b (32.1%), 1b (4.9%), 1a (2.5%) and 3g (1.2%).
Newer, short-course, andwell-tolerated therapies have become
available and it is being suggested that “Treatment as Prevention”
be undertaken as a strategy in PWID to reduce onward HCV trans-
mission. Sucha strategy couldbecomepart of a comprehensiveHCV
disease elimination strategy.
http://dx.doi.org/10.1016/j.ijid.2016.02.134
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Abstract: Signiﬁcant progress has been made in treatment of
hepatitis C (HCV) infection since the virus was discovered over 26
years ago. After introduction of directly acting agents (DAAs), the
treatment for hepatitis C has signiﬁcantly improved both in efﬁcacy
and tolerability. Clinical trials using combinations of DAAs have
shown excellent sustained viral response rates (SVRs) in patients
with all HCV genotypes. Hepatitis C has now become a curable
disease from a chronic disease, and complications such as liver cir-
rhosis and hepatocellular carcinoma (HCC) are preventable. Given
the safety and efﬁcacy, treatment of HCV can move to the realm
of primary care physicians. However, with availability of multi-
ple DAAs in the market and several more on the pipeline, it has
becomemore complex todecidewhich combination therapywould
be more appropriate for individual patients. Additionally, despite
an abundance of choices, the cost of drugs has become a major hin-
drance to access for many patients. This presentation will provide
an overview and update on treatment of hepatitis C infection.
http://dx.doi.org/10.1016/j.ijid.2016.02.135
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Abstract: Infection with HIV and HCV contributes substantially
to the global burden of disease, with an estimated 4-5 million
people living with both infections. The natural history of HIV and
HCV is signiﬁcantly impacted by the coexistence of the other virus.
Increases in all-cause, AIDS-related, and liver-related morbidity,
hospitalization, and mortality are noted, with accelerated liver dis-
ease progression and high rates of end-stage liver disease, even in
those receiving combination antiretroviral therapy (cART) Given
greater access to cART, the number of global deaths related to HIV
is falling. In contrast, the number of HCV- related liver deaths is
rising. Fortunately advances in the development of directly acting
antiviral (DAA) agents for the treatment of HCV now mean that
highly effective, all oral regimens with low toxicity can be use to
achieve sustained virological response (SVR) in themajority ofHIV-
HCV co-infected individuals. However high cost and limited access
to these drugs currently prevent theirwidespread use, especially in
low and middle income countries. This paper will review the epi-
demiological data on prevalence of HIV-HCV globally and discuss
the natural history of co-infection.Most recent data on trials of DAA
combination therapy in HIV positive people will be presented and
issues relevant to this population including drug-drug interactions
reviewed. Finally barriers to care and treatment relevant to global
settings will be discussed.
http://dx.doi.org/10.1016/j.ijid.2016.02.136
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Abstract:Outbreaksandsporadic casesofhepatitis Eoccurglob-
ally with large epidemics occurring in resource-limited regions
where there is over-crowding, unsanitary conditions and poor
health services including refugee camps and internally displaced
populations. The World Health Organization (WHO) estimates that
the virus infects 20 million people each year of which 3 million
are acute hepatitis cases and 56,600 die. Fulminant hepatic failure
is reported in those infected in the third trimester of pregnancy
in some regions. Hepatitis E virus (HEV) infection can lead to
hepatitis decompensation in those with pre-existing liver disease.
Chronic HEV infection has been reported in solid organ transplant
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patients and those on immuno-suppression. There are four known
genotypes of HEV. The most recent candidate vaccines have been
two recombinant HEV vaccines. The ﬁrst of these vaccines was
based on a 56-kDa baculovirus-expressed ORF2 protein produced
in Spodoptera frugiperda cells, developed at the National Institutes
of Health, later licensed to GlaxoSmithKline. A phase II clinical
trial was conducted in 1,794 young male military recruits in Nepal
who received three doses 20g of the alum-adjuvanted vaccine
or placebo. Vaccinees were followed up to 2.2 years. The vaccine
showed a 95% efﬁcacy after the third dose. This vaccine study was
limited by the fact that it was tested on almost exclusively young
males, it did not measure the HEV infection rate and that antibody
titers declined by the end of the study. The second vaccine was
developed by researchers at Xiamen University in China, using a
new recombinant HEV protein expressed in Escherichia coli. This
vaccine, HEV 239 (Hecolin), was tested in a randomized, controlled
trial involving 112,604 healthy participants aged between 16-65
years in Jiangsu Province, where HEV genotypes 3 and 4 are more
prevalent. In those who received all three doses, 87% maintained
antibodies and remained protected against HEV for up to 4.5 years.
Its efﬁcacy against HEV genotypes 1 and 2, in pregnant women and
those younger than 16 years and older than 65 years are yet to
be assessed. The vaccine is licensed for use in China. Though not
yet prequaliﬁed by the WHO, the WHO is ready to assist national
health authorities and regulators in a rapid assessment of this vac-
cine. Today, the real challengewill be to get anHEVvaccine to those
who need it the most, at an affordable price.
http://dx.doi.org/10.1016/j.ijid.2016.02.137
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Safety, immune lot-to-lot consistency and
non-inferiority of a fully liquid pentavalent
DTwP-HepB-Hib vaccine: Results from Phase III
licensure study of Shan5TM
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Background: Pentavalent combination vaccines perform a key
role in increasing vaccine coverage rate; and provide an efﬁcient
and reliable method of implementing WHO recommendations for
controlling diphtheria, tetanus, pertussis, hepatitis B andHib infec-
tions on a worldwide basis.
Methods & Materials: Study design: A phase III, multi-center,
randomized, single blinded study of a fully liquid pentavalent
DTwP-HepB-Hib investigational vaccine (Shan5TM) was conducted
across India in healthy toddlers and infants. Cohort 1 consisted of
15 toddlers aged 15-18months, administeredwith a single booster
dose; Cohort 2 consisted of 1085 infants aged 6-8 weeks, adminis-
tered 3 doses at 6-8, 10-12 and 14-16 weeks of age.
Objectives: Subjects in Cohort 1 were evaluated for safety and
immunogenicity. Immunogenicity and safety were evaluated in
Cohort 2 subjects vaccinated with a three-dose primary immu-
nization of either the investigational vaccine or a locally licensed
comparator vaccine (PentavacTM SD). Immune consistency anal-
ysis among three lots of the investigational vaccine, and immune
non-inferiorityanalysisofpooled (three lots)dataof investigational
vaccine versus comparator vaccine were also evaluated in cohort
2.
Results: The vaccines demonstrated comparable safety and
immune responses in cohort 1. In cohort 2, immune non-inferiority
against the comparator vaccine (primary endpoint) was demon-
strated for all ﬁve antigens and safety results (secondary endpoint)
were comparable between vaccine groups. Equivalent immune
consistency among three lots was observed for all antigens except
whole cell pertussis antigens, where a marginal variation was
observed. The variation was linked to the low power of the test
and concluded to be clinically insigniﬁcant.
Conclusion: The investigational, fully-liquid,whole-cell pertus-
sis (wP) containing pentavalent vaccine has a good safety proﬁle
and immunologically non-inferior to the licensed comparator vac-
cine. This study was the basis for licensure in India and also WHO-
prequaliﬁcation for international use.
http://dx.doi.org/10.1016/j.ijid.2016.02.138
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Background: Studies on county-level hot spots of sexually
transmitted infections (STIs) in the entire U.S. and their associ-
ation with socio-economic factors are lacking. In this study, we
used a combination of hot spot analysis (HSA) and spatial regres-
sion to examine the county-level correlates of the most commonly
reported curable sexually transmitted infections (STIs) in the U.S.
Methods & Materials: We obtained reported county-level total
case rates of chlamydia, gonorrhea, and primary and secondary
(P&S) syphilis in all counties in the 48 contiguous states using
the National Notiﬁable Disease Surveillance System (NNDDS).
We computed temporally-smoothed rates using 2008–2012 data.
Covariateswereobtained fromcounty-levelmultiyear (2008-2012)
American Community Surveys (ACS) from the US census. We con-
ducted HSA (applying the false discovery rate (FDR) correction) to
identify hot spot counties for all three STIs. Hot spots were deﬁned
as counties or clusters of countieswith rates above the globalmean
(p<0.05). We used logistic spatial regression with the spatial error
model (SEM) to determine the association between hot spots and
the covariates and variance inﬂation factor (VIF <10) analysis to
reduce the effect of multicollinearity on the coefﬁcients.
Results: HSA indicated that ≥ 80% of hot spots for each STI were
in the South. Spatial regression results indicated that, compared to
White non-Hispanics, a 1% increase in the percentage Black non-
Hispanic was associated with a 3.3% (p<0.01; chlamydia), 3.8%
(p<0.01; gonorrhea) and 2.5% (p<0.01; P&S syphilis) increase in
the odds of being a hot spot county (Table 1). Compared to the other
regions (West, Midwest andNortheast), counties in the Southwere
